Twice-Yearly Biologic Shows Long-Term Safety in Asthma
A 12-month interim analysis of the AGILE Phase III open-label extension study confirms that twice-yearly depemokimab, an ultra-long-acting anti-IL-5 biologic, maintains a favorable safety and efficacy profile in patients with type 2 asthma.